Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You are right. People flock to the trend. Wish there was a bit more momentum behind ONC. Will just take a little longer and will need more press
There doesn't appear to be any risk appetite at the moment. Perhaps all the smart money is heading over the Atlantic to AI related Nvidia, which is ever stronger...it's going to end in tears and probably drag us all down with it!
Can someone give me a reasonable explanation for the dramatic and earth shivering weakness of this companies shares?
We have to stay positive otherwise you end up looking at the numbers from the Annual report in a less favorable way. Context is key
Set out like that it all looks pretty good.
fingers crossed the market agrees.
Started: Elrathia, 6 Jun 2024 16:05
Last post: R00st3R, 7 Jun 2024 09:30
I just topped up with as much as I could scrape together. Honestly, at 0.16/share it's a great opportunity to bring down my averages. I believe strongly in the capability of this management team to execute. So much progress has been done commercially. They are aiming to be profitable within a year. What else is there to ask of a business. The world need to learn more about ONC. To make the highly specialised value proposition clear to investors that do not fully understand the science and the technicalities. I think it would be beneficial to publish a case study with a clear perspective on the customers' ROI
Frustrating. Leaves me wondering how the investors react to the expected revenue for the Finanvial year, which is almost certainly above 300% of last year's revenue. The company needs more cash for Marketing and PR.
A big drop today on no news. and very few trades. perhaps an opportunity to buy some cheap shares and watch it bounce tomorrow? who knows i wish i did then i'd be rich
Started: R00st3R, 31 May 2024 14:35
Last post: Pharmhall, 2 Jun 2024 12:20
Thank you for the Vox interview...so escrow money (£1.17m) is already in bank...good news. CEO also states that it has sufficient working capital for 12 months (albeit not on my numbers). But even if he is right the loan covenant is for constant 9months w/c requirement, so even by his reckoning it will need capital in 3 months time to cover the covenant. Also, he states that activity is being constrained by cash levels. I like what company does and the management team, but how things could be so much better with more cash.
If the perceived risk of the money not turning up is why the share price fell 19.6%, then it's ill informed fear. Could also be random sells combined with low volume of trades.
No one should fear a fundraise at this point: for the first time in several years, things are turning around in a positive fashion. Long painful journey for many of us long term holders!!
No guarantees obviously, this is business!
Vox Markets interview; see from around 16:20
https://youtu.be/SEF0mbr_Uy0?feature=shared
CEO: "we received the funds already"
Probably OK for a year forward, but could do with more cash for expansion. A fundraise, if any, most likely a positive event in my opinion.
The money were released. There is nothing to watch. Maybe later in the year!
In its last statement, company stated that it had applied for the cash being held in an escrow account which was due for payment in May. Today is the last day. If it has not come in, I do not believe that it will pass the monthly covenant test and will require an urgent Placing. Watch this space!
Started: Troajan, 24 May 2024 18:50
Last post: Troajan, 24 May 2024 18:50
Started: Pharmhall, 21 May 2024 17:35
Last post: Pharmhall, 21 May 2024 17:35
Interims were in line with expectations today showing that the new strategy is gaining traction. Management reiterated the £3m sales expectation for fully year and that order book is looking good. £2.3m cash was absorbed in the period, leaving gross cash of £0.91m. Company has requested release of £1.17m cash held in escrow from disposal, which will be needed to get ONC through to year-end in August. Company needs to prove each month it has 9months working capital on balance sheet at all times to satisfy loan covenants. This will not be the case as the fiscal year proceeds, so will need a cash call soon.
Move to profitability looking closer?
Any thoughts on interim results?
23.04. MG at Proactive London."Martin Gouldstone, Oncimmune’s Chief Executive Officer, said: “As ageing-related diseases become more prevalent in society we believe that our ImmunoINSIGHTS technology can be instrumental in finding better diagnosis and treatment solutions for these diseases, while making clinical trials more efficient and productive. We are working closely with our partners in this area and I look forward to discussing the topic with world-leading experts later this month.”
"The company is already working with leading drug discovery companies on ageing-related research and has been approached by several global pharmaceutical companies about the use of its technology in this field."
Time will tell but I have observed this company for a while now and I guarantee that the upside potential for this is tremendous. The diagnostics market is poised to expand considerably over the coming years and with the diverse application of ONCimmune's service, I think deals will be closed. Many deals.
I also believe that the (Bio-) Pharma industry is awake and on the up again. Coming out of a prolonged period of under investment and bearish sentiment, there is a lot more activity on the M&A market. I can see a bull charging from the distance
Probably right. Someone certainly thinks there is reason to buy.
Last post: RampantRumpole, 18 Apr 2024 12:42
I bought a modest amount of shares at 21p. It was mainly based upon a sudden 12% jump and the RNS about meeting thresholds and declaring interest. There seemed to be few but chunky buys. There was zip on this board. I'm no expert at all and probably not a sensible reason to buy, but I have seen one of the board, Goold, mentioned in other articles. They seem like they have their heads screwed on and are serious people.
In the most recent report from Feb 24, it was indicated that H1 FY24 results should be made public via a trade update in May. I assume that the shares will start to get bought up because it is a phenomenal entry price for a business that will have their first 'clean' report post sale of non-core assets. This report will show an expected high increase in revenue and possibly reveal a rich and growing pipeline. At this point the strategy I'd defined, the resources are all hired, the overheads are gone and the margins are wide. On top of that there is a solid baseline revenue from existing contracts incl. Freenome and other MSA and ongoing projects. Many more to come. I believe we are at the 'tipping point' right now.
I hope others agree. Curious to read other opinions. But I cannot see the SP going back down from here, quite the opposite
Something is going on here. Anyone know if a trading update is expected?
Started: DrPatience, 18 Mar 2024 10:03
Last post: R00st3R, 18 Mar 2024 19:04
AIM moves in mysterious ways.
Sure these stocks will start getting gobbled up with the Mai FY24 H1 results. If we can see a strong growth trajectory
Falling even with buys...
Someone clearing out their big holding (for whatever reasons) or the usual AIM circus??
Great value though, will consider buying more!
Started: Troajan, 6 Mar 2024 07:56
Last post: R00st3R, 15 Mar 2024 08:59
I wish i had some spare change right now... ONC taking a big hit knocking off 20%. At these levels a definete buy to get the average down.
Like you said Dr. This is a long game but i firmly believe that the latest report will have been the worst summing up a year of change and metamorphosis.
I think right now is when the cocoon cracks...
Theboyg, I think they are doing the right things: setting the company up for sales and growth. It may take time to demonstrate further they are on the right track. Results going forward will show if this is real or just fluff. The tech is really quite special and should be a winner going forward. Good entry point. Very thin trade though, I think most long term holders do just that: hold!
Pardon, ...sale of Oncimmune Limited and Oncimmune Europe GmbH
I have not. I think the company has been in this spot here 2 years ago when the Sales strategy and structure was laid out by former CEO. Company needs to prove that debt to equity ratio is solid and not spiral out of control. I think there should be a check around that given reduced overheads from asset sale.
The other component is proof that there is sustainable and predictable growth in the stock. I hope 150% is the start to a consistent acceleration based on repeat customer contracts MSAs and longer term commitments as from Freenome.
Sad to say it may take another couple of reports for this to recover but based on the fugures (unmuddied by sale of Oncimmune Plc), right now i think is a smashing SP.....if you believe in thw longer term prospects of the business. I do
Anyone attend webinar??
Down since then
I watched video
Unimpressive I thought
Started: VValrus, 1 Mar 2024 11:03
Last post: R00st3R, 1 Mar 2024 17:01
1 trade today? Any takers?
Anyone else want to put a penny in the tin?
No? Alright - have a great weekend all.
Its not untypical for an acting CEO to be on the boards of multiple companies. If anything i see this as a positive for Networking/ business opportunity and validation of their quality.
Started: R00st3R, 29 Feb 2024 07:54
Last post: R00st3R, 29 Feb 2024 07:54
Hi all. I am reading a highly encouraging report with exciting prospects, growth and marging expansion.
Revenue in FY 2024 expected to be approximately £3m, compared with FY 2023 revenue from continuing operations of £1.2m, a growth rate of 150%. Coming up to the end of H1 FY 2024, work to achieve approximately 75% of the forecast FY 2024 revenue has been secured, with the majority of samples received or expected imminently allowing lab work to begin and revenue to be recognised in due course.
Started: R00st3R, 24 Jan 2024 15:34
Last post: R00st3R, 28 Feb 2024 15:58
Terribly sorry for the typos. On my phone.
Sorry to hear that mc. You are not the only one with a gaping loss %.... many have already jumped ship and some have not yet cut the cord.
Lots of frustration here with this SP. Freenome doing very well esp since acquisition of non core ONC business. As for ONC now i just could not imagine this business failing to capitalise on their pole position and the largely untapped market. With ONCs margins and new structure leadership and commercial approach etc i would question whether every little thing in this world if this was not the bottom of where this SP sits.
Years ago they made 170k revenue and shares traded at close to 1GBP.
This could have been due to low i terest rates and the pote tially great growth prospects. I expect strong growth guidance from leadership and over time i terest rates will go down too. OnC is already making tons more revenue than 170k.
To all here. Am I naive in wanting to hold for another fiscal at the minimun to seethe pendulum finally swing the other way?
Well, I finally bailed on Monday after sitting on a 90% loss for far too long. Knowing my luck, you guys are in for a treat soon, lol!
I see this stock being traded down coincidentally in line with wider market movements.
#PCE reading
# GDP data
Is there another reason we are seeing 9%drop today. Or are we just bracing for the number we are about to be exposed to for FY23.
Wait and see. The commercial update from Martin end of November sounded very promising.
Started: Troajan, 1 Dec 2023 11:12
Last post: Troajan, 1 Dec 2023 11:12
Started: DrPatience, 25 Nov 2023 11:14
Last post: R00st3R, 29 Nov 2023 17:43
I want to agree with you on the confidence in new leadership and strategy as well as Presentation well received part. I had topped up as well after watching the interview. Addressable market is enormous and as mentioned hard to predict exact size because the boundaries of the application of ONC ImmunoInsights are ever expanding. Perhaps interest rate developments just coincide with the news coming from ONC. Maybe the combination is doing the trick.....in any case we have a highly motovated leadership that knows Big Pharma and Biotech and have been hired for their ability to scale ONC from single digit mio revenue to multi-digit revenue company.
Commercial focus
Investors in mind
Bleeding edge of Innovation (Luminex and AI....)
Leader in industry
Hardly any comparable comüetition
MSAs with Big Pharma companies
Established Sales Team
Time to crush it!
(Probably another 3-5 year hold..... then i may consider retirement....please!!!)
Faith in new CEO/ new plan? Presentations and interview well received?
I am doubtful about interest rates having an impact at all at this point.
It was oversold as if it would collapse, which clearly is not the case. They are back fighting with a vengeance !!
Annual resuls will be a disaster in my view (baked in and more), but I think the new plan will carry more weight that the past failures, so could well continue to move up. The potential for this business is enormous.
Nice pop in the SP. Again could be due to the news around interest rates.
My take is that as inflation goes down and Central banks start mulling the decrease in interest rates we will see a natural lift in the market. For ONC specifocally the coming Report will be interesting as there should be a good foundation of revenue stemming from the following 3 partnerships alone: Biodesix, Freenome and Siemens Healthineers, not to speak of all other business we have not been exposed to as much.
I have a feeling that similar to how fast the SP crashed, we may see it go back up again.
Super excited about the prospects.
Great find. The one day i didnt scan the market for news. ^^ have been waiting for this interview for a bit. And absolutely confident that we will see this business realise revenue from all the contracta they have landed to date and new ones they are landing. I am holding tight man!
Courtesy brummy_git over at ADVFN:
https://www.youtube.com/watch?v=hOsXNm-r3LQ
Worth watching. I feel this has been a big reset and looking forward to results going forward!
Started: R00st3R, 15 Nov 2023 13:19
Last post: DrPatience, 18 Nov 2023 08:42
Well, clearly something going on!!
A real investor making a genuine punt + FOMO?; or just pump&dump?; or insider info leaked to analysts, friends&family? TBC, only time will tell.
However, if you believe in the new strategic focus and that they can execute then the share is clearly hugely undervalued, especially if you look at the prospects for high margin revenue.
There seems to have a small relly in a few small caps incl ONC on AIM....could be inflation related with the sharp drop from recent readings (4.6%)
Seems unlikely to be random. Over the last few weeks we have not seen more than 3-4 trades a day. 10 folding that today. Guessing investors know about something
Insider info - news coming?
Or just speculation?
Feels random.
Nice little boost there for the struggling SP. 22% from nearly nothing makes it nearly something. Lets keep going. 22 trades with highest trade at 14k....seems like it doesnt take much to move the needle here.
Started: DrPatience, 23 Oct 2023 11:21
Last post: R00st3R, 9 Nov 2023 20:12
No doubt they will need to rationalise it all. Reflect the revamped strategy and provide some forward looking statements. We may learn a nice thing or two from commercial successes. Last TU was more than 6months ago...
Would be nice to get the annual results out of the way!!! It's going to be a car crash, but I'm positive about the future given the strategic reset.
Just watched the recording. Like you mentioned there seems to be a lot of untapped potential for ImmunoInsights. Slim competition and a big addressable market especially when the Big Pharmas/and Biopharmas etc are seeing value of such antibody profiling services during the CRO cycles. I think that this address to the investors was important to win back some confidence and I thank Martin for delivering the message to the investors that a more predictable growth and revenue is needed an this is being implemented now too. I hope this also means that we can get some guidance in the coming reports on what to expect. You see these days, much of what is being invested is based on future growth. And without any reliable prediction or forecast all this goes out the window. Hence why ONC trades at these levels. Growth is baked in to the current SP at the most conservative level...
Looking forward to the year ahead with this business.
Thanks Doc....I will review the recording too when I get a chance today. It all sounds so promising. Oh how I wish today was my first day to know ONC. What an SP indeed. Similar to yourself I was bought in with Early-CDT, first but around the ECLS study. I think that is why the asset sale was a bit of a punch to the gut. But it seems like we should be on the up soon again.
You can watch a recording on the Investor meet Company website. I have just done the same, had to be somewhere else yesterday.
In anutshell: unique IP with little competition, technology ripe for exploitation, a credible team and strategy, including renewed commercial focus/approach and new focus areas, like diabetes and neuroscience. Potentially a lot more value to be realised. They can actually potentially do a hell of a lot more than I thought, having originally bought in due to EarlyCDT only.
Now we need solid financial progress going forward. Past financial performance leaves a lot to be desired, but that's also why the share price is so low. They will also be looking to create more stable, recurring income streams, which is good for stability and investor nerves in particular!!
Started: R00st3R, 26 Sep 2023 16:56
Last post: DrPatience, 17 Oct 2023 09:05
Difficult to say, could also reach 10p until we start seeing financial progress tbh. Almost random until we have more news. Having said that, most investors, including the large investors, are holding on to their shares; very thin trading.
I am also very optimistic.
The large investors are no doubt waiting patiently for a corporate takeover/exit. They paid a lot more for their shares than the current price, so lowball offers should be rejected.
I am actually for once super optimistic. Think we must have hit the bottom.
https://www. v o x markets.co.uk/articles/oncimmune-shifts-strategy-to-accelerate-commercial-expansion-871f174/
I agree, everything sounds very sensible. If they are at 20-30% capacity then I would be more than happy, as I think they have been running at a lot less during the first half of the financial year.
I like the clarity and focus. This is all about ramping up the numbers.
The proof is in the pudding - let's see the numbers.
It may be another year before we see real, significant progress, but that's OK! The share price will then follow suit!!
Sorry....CAPEX reduced due to sale of assets to Biodesix and Freenome whilst longer term revenue secured at least for next couple of years. OPEX I think overall down due tonlower overheads. Not sure how the employee salaries play into this number as many expensive new hires incl execs but also terminated contracts. More sales improves bottom line as more lab capacity used. I feel it is currently heavily under capacity (probably around 20-30%)?
Interesting updates. You can tell that the leadership team is focussing on establishing sales structures that cater for different customer segments but as it looks all gearing to supporting long term partnerships, becoming an essential partner in CRO cycles and generating revenue through existing and new long term MSAs. CAPEX significantly reduced as the upfront lift of establishing a competent sales team in US and UK was done over the last couple of years and with that getting these key account MSA's signed. Hopefully we can see demand picking up and and lab facilities being used at higher capacity.
New strategy means some more from the old guard are leaving and the focus seems clearly on generating long term sustainable revenue and doing more of the above.
I suppose this years number will be a bit skewed again because of the Onc Ltd. Balances being included still. Will be interesting to read in the coming weeks/months.
Started: JaysonBin, 11 Sep 2023 04:38
Last post: JaysonBin, 11 Sep 2023 04:38
I have raised the quantity in order to test the possibility of causing an avalanche. Nevertheless, we anticipate receiving news shortly.
Started: JasonPanda, 11 Sep 2023 03:32
Last post: JasonPanda, 11 Sep 2023 03:32
I have increased the amount to observe if I can trigger an avalanche. Regardless, news is expected soon.
Started: MichaelLiamsiTtG, 10 Sep 2023 21:09
Last post: MichaelLiamsiTtG, 10 Sep 2023 21:09
I added more to see if I can cause an avalanche. In any case, news should be imminent.
Started: CuauhtlecoRodasv, 10 Sep 2023 15:21
Last post: CuauhtlecoRodasv, 10 Sep 2023 15:21
I added more to see if I can cause an avalanche. In any case, news should be imminent.
Started: R00st3R, 30 Aug 2023 10:13
Last post: DrPatience, 8 Sep 2023 08:29
Wait for corporate takeover... may take time though!
I am a fool for hoping to make a profit, in a marketpleace with 3 other people
It's a long and drawn out affair. How the days, the weeks, months, yes even the years have gone by. And still I remain loyal to ONC. For all I can tell,
I agree! Another day of no news, but someone selling (randomly). Waiting for cash to come in, will add if still this low!!
Now I wish I had been more patient.this drop looks like a nice buying price again
Started: stargate, 31 Jul 2023 03:22
Last post: R00st3R, 15 Aug 2023 11:27
Hey Dr. P.
No idea. We have two more weeks to the end of the quarter and year. I would imagine a TU to be around the corner to indicate generic updates ahead of the Annual report which I could imagine will be available sometime end of September, early October. But I don't think anyone really knows. I am seeing some more traction in the overall Biotech / Biopharma space. With earnings season in full swing and continuous focus on new drug development and vaccines etc. I like most of us are probably itching for some news.
Either way, the hurdles are out of the way. Let us see how the business seeks to maximise operational efficiency, sales and balance with lab capacity. At this point is feel like the numbers need to do the talking
Trek, good luck, the sp seems stuck though with hardly any trades...I guess only news will really shift things (up or down...)
Does anybody know when next trading update is due?
Took some profits today along with others it seems. Will feed back in if it goes lower.
Trek
Fast movement confirmed by separating Bollinger bands, sp, target is 35, is higher bottom of 29/3/23. There is a price pivot low, at 36, dated 13/2/20, which if overcome, could imply further upside.
Aside from the profit target, above of 35, if the lower Bollinger band, which is currently falling , begins to turn up, expect a retracement, and take profit, by selling. Subsequent re-entry into the equity, can be considered on a close above preceding high, or if RSI, crosses above 50.
Started: TrekMadone, 12 Jul 2023 07:35
Last post: theboyg, 27 Jul 2023 23:02
Trek
I agree
As usual… I too am tied up. I’d love to be wealthy. So much to make
50p post results
So much upside!!!!
I need a guitar and a hat!!!
As soon as stock comes up it’s bought.
I wish I could add here but holding elsewhere for news. Cost me DEST as well where I was going to buy back!
I really don’t see this going any other way than up. The sht news is in the price. It’s just going to be documented in the interims the market will then see the debt payments. Then it’s all about high margin sales and the outlook from the new BoD and TF we have a new CFO!
Usual caveats
Trek
Honestly it is a combination of thing in my view.
o Salaries coming in
o New CEO joining in matter of days
o Fed Reserve meetings yesterday and today
-pot. last 1-2 rate hikes ahead
o Q2 earnings season
o Upcoming end of financial year for ONC (Aug 31st)
-balance sheet will 100% be better than last
o Investors reshuffling portfolios now
o director buys
Etc.
But who knows what is really driving the trades. If it is director buys we should get RNS soon on that.
Trek, same here. Could be director buys being built up or clusters of investors or just lemmings :-)
Clearly there is no fresh news yet, unless people have insider info.
I am hoping it wall fall back again, so I can top it up, too (waiting for cash to come in also!!)
Patience will pay off in my view!
Theboyg, I am wondering what you mean by "But the value has been zapped!!!"? Perhaps you could elaborate, please?